Skip to content

Imatinib

Imatinib (Gleevec) is a kinase inhibitor used in the treatment of chronic myeloid leukaemia and gastrointestinal stromal tumours, with one formulation listed in this catalogue.

Gleevec

Chronic Myeloid Leukaemia

400mg

Imatinib tablets for chronic myeloid leukaemia and stomach tumours. It disables the abnormal protein that fuels the growth of leukaemia cells.

From$10.63/ tabletView

Key points

  • Imatinib blocks a protein called BCR-ABL that signals cancer cells to multiply.
  • Common side effects may include fluid retention, nausea and tiredness.

About imatinib

Imatinib is the active ingredient in Gleevec, the originator brand from Novartis and the sole formulation in this oncology support catalogue. Each imatinib tablet is a 400mg product used in the treatment of chronic myeloid leukaemia and gastrointestinal stromal tumours.

Further reading